Autologous CD34 Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study

Autologous CD34 Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study

An increasing number of patients have refractory angina despite optimal medical therapy and are without further revascularization options. Preclinical studies indicate that human CD34 + stem cells can stimulate new blood vessel formation in ischemic myocardium, improving perfusion and function. In A...

Full description

Bibliographic Details
Main Authors: Timothy D. Henry, Gary L. Schaer, Jay H. Traverse, Thomas J. Povsic, Charles Davidson, Joon Sup Lee, Marco A. Costa, Theodore Bass, Farrell Mendelsohn, F. David Fortuin, Carl J. Pepine, Amit N. Patel, Norbert Riedel, Candice Junge, Andrea Hunt, Dean J. Kereiakes, Christopher White, Robert A. Harrington, Richard A. Schatz, Douglas W. Losordo
Format: Article
Language:English
Published: SAGE Publishing 2016-09-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/096368916X691484

Internet

https://doi.org/10.3727/096368916X691484

Similar Items